Alkermes dropping ALKS 33 for binge eating

Alkermes Inc. (NASDAQ:ALKS) discontinued development of ALKS 33 to treat binge eating disorder after data from a Phase II trial showed that the opioid receptor modulator did not significantly reduce self-reported weekly binge eating episodes from baseline to week 12 vs. placebo. Alkermes said it will continue to develop the compound in other CNS indications, including alcohol dependence. ...